Background: LC3 serves as a marker for assessing autophagy activity in cancer cells, which is a potential focus for therapeutic interventions. It holds the potential to serve as a predictive indicator of resistance to chemotherapy in colorectal cancer. Thus, this study is aimed at finding the association between LC3 expression, metastasis, and chemotherapy response in colorectal patients. Methods: This study was an observational study evaluating the stage and chemotherapy response of a colorectal cancer patient in a tertiary hospital in West Java, Indonesia. The research participants included in this study were 83 subjects. The examination of LC3 was performed with immunohistochemistry. The response evaluation criteria in solid tumors (RECIST) were used for the evaluation of the chemotherapy response. Results: A positive LC3 expression was shown in 58 (69.9%) patients. In positive LC3 expression, 20 subjects (27.4%) showed progressive response, 16 subjects (21.9%) showed stable response, 12 subjects (16.4%) showed partial response, and 1 subject (1.4%) showed complete response. Meanwhile, in negative LC3 expression, 12 subjects (16.4%) showed progressive response, 8 subjects (11%) showed stable response, 3 subjects (4.1%) showed partial response, and 1 subject (1.4%) showed complete response. The LC3 expression showed no significant relationship with age, sex, subtype, grade, tumor location, stage, or chemotherapy response (p > 0.05). Conclusion: The expression of LC3 showed no significant relationship with metastasis or chemotherapy response.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018, 68(6): 394-424. doi: 10.3322/caac.21492

2. Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023, 73(3): 233-254. doi: 10.3322/caac.21772

3. Dulskas A, Gaizauskas V, Kildusiene I, et al. Improvement of Survival over Time for Colorectal Cancer Patients: A Population-Based Study. Journal of Clinical Medicine. 2020, 9(12): 4038. doi: 10.3390/jcm9124038

4. Kemenkes RI. National guidelines for the management of colorectal cancer (Indonesian). Jakarta: Menteri Kesehatan RI. 2018; pp. 9–27.

5. Yamagishi H, Kuroda H, Imai Y, et al. Molecular pathogenesis of sporadic colorectal cancers. Chinese Journal of Cancer. 2016, 35(1). doi: 10.1186/s40880-015-0066-y

6. Rabinowitz JD, White E. Autophagy and Metabolism. Science. 2010, 330(6009): 1344-1348. doi: 10.1126/science.1193497

7. Levine B, Kroemer G. Autophagy in the Pathogenesis of Disease. Cell. 2008, 132(1): 27-42. doi: 10.1016/j.cell.2007.12.018

8. Wang Y, Zhao Z, Zhuang J, et al. Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer. Journal of Cancer. 2021, 12(12): 3515-3528. doi: 10.7150/jca.51430

9. Schmitz KJ, Ademi C, Bertram S, et al. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World Journal of Surgical Oncology. 2016, 14(1). doi: 10.1186/s12957-016-0946-x

10. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biology & Therapy. 2013, 14(2): 100-107. doi: 10.4161/cbt.22954

11. Wu S, Chenbo S, Yangyang L, et al. Autophagy-related genes Raptor, Rictor, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma. Human Pathology. 2015, 46(11): 1752-1759. doi: 10.1016/j.humpath.2015.07.016

12. Lock R, Roy S, Kenific CM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Yoshimori T, ed. Molecular Biology of the Cell. 2011, 22(2): 165-178. doi: 10.1091/mbc.e10-06-0500

13. Wu S, Sun C, Tian D, et al. Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. International Journal of Clinical and Experimental Pathology. 2015; 8(4): 3882.

14. Zhao H, Yang M, Zhao B. Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal carcinoma. Oncotarget. 2017, 8(35): 59058-59067. doi: 10.18632/oncotarget.19939

15. Recio-Boiles A, Cagir B. Colon cancer. Available online: https://www.ncbi.nlm.nih.gov/ books/NBK470380/ (accessed on 6 July 2023).

16. Cuschieri S. The STROBE guidelines. Saudi Journal of Anaesthesia. 2019, 13(5): 31. doi: 10.4103/sja.sja_543_18

17. Beer L, Hochmair M, Prosch H. Pitfalls in the radiological response assessment of immunotherapy. memo - Magazine of European Medical Oncology. 2018, 11(2): 138-143. doi: 10.1007/s12254-018-0389-x

18. Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. British Journal of Cancer. 2002, 87(4): 393-399. doi: 10.1038/sj.bjc.6600467

19. Leicher LW, de Graaf JC, Coers W, et al. Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs in R&D. 2017; 17: 117-24. doi: 10.1007/s40268-016-0154-8

20. Mármol I, Sánchez-de-Diego C, Dieste AP, et al. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017, 18(1): 197. doi: 10.3390/ijms18010197

21. Recio-Boiles A, Kashyap S, Tsoris A, et al. Rectal cancer. Available online: https://www.ncbi. nlm.nih.gov/books/NBK493202/ (accessed on 6 July 2023).

22. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. J Gastrointest Oncol. 2012; 3(3): 153–73. doi: 10.3978/j.issn.2078-6891.2012.030

23. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Annals of Translational Medicine. 2019, 7(21): 609-609. doi: 10.21037/atm.2019.07.91

24. Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2): 338-344. doi: 10.1136/gutjnl-2022-327736

25. Mahgoub E, Taneera J, Sulaiman N, et al. The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Frontiers in Medicine. 2022, 9. doi: 10.3389/fmed.2022.959348

26. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. The International Journal of Biochemistry & Cell Biology. 2004, 36(12): 2503-2518. doi: 10.1016/j.biocel.2004.05.009

27. Chen Z, Li Y, Zhang C, et al. Downregulation of Beclin1 and Impairment of Autophagy in a Small Population of Colorectal Cancer. Digestive Diseases and Sciences. 2013, 58(10): 2887-2894. doi: 10.1007/s10620-013-2732-8

28. Yang M, Zhao H, Guo L, et al. Autophagy-based survival prognosis in human colorectal carcinoma. Oncotarget. 2015, 6(9): 7084-7103. doi: 10.18632/oncotarget.3054

29. Burada F. Autophagy in colorectal cancer: An important switch from physiology to pathology. World Journal of Gastrointestinal Oncology. 2015, 7(11): 271. doi: 10.4251/wjgo.v7.i11.271

30. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. The Journal of Pathology. 2010, 221(1): 3-12. doi: 10.1002/path.2697

31. Devenport SN, Shah YM. Functions and Implications of Autophagy in Colon Cancer. Cells. 2019, 8(11): 1349. doi: 10.3390/cells8111349

32. Vodenkova S, Buchler T, Cervena K, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacology & Therapeutics. 2020, 206: 107447. doi: 10.1016/j.pharmthera.2019.107447

33. Lee YK, Lee JA. Role of the mammalian ATG8/LC3 family in autophagy: differential and compensatory roles in the spatiotemporal regulation of autophagy. BMB Reports. 2016, 49(8): 424-430. doi: 10.5483/bmbrep.2016.49.8.081

34. Manzoor S, Saber-Ayad M, Maghazachi AA, et al. MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma. Neoplasia. 2022, 24(2): 76-85. doi: 10.1016/j.neo.2021.12.003

35. Tang JC, Feng YL, Liang X, et al. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer. Chinese Medical Journal. 2016, 129(4): 456-463. doi: 10.4103/0366-6999.176069

36. Guo GF, Wang YX, Zhang YJ, et al. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World Journal of Gastroenterology. 2019, 25(15): 1840-1853. doi: 10.3748/wjg.v25.i15.1840

37. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: A Cancer Journal for Clinicians. 2017, 67(2): 93-99. doi: 10.3322/caac.21388

38. Guo GF. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World Journal of Gastroenterology. 2011, 17(43): 4779. doi: 10.3748/wjg.v17.i43.4779

39. Khokher S, Qureshi MU, Chaudhry NA. Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2012, 13(7): 3213-3218. doi: 10.7314/apjcp.2012.13.7.3213

40. Shim BY, Sun DS, Won HS, et al. Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy. BMC Cancer. 2016, 16(1). doi: 10.1186/s12885-016-2250-0